Please use this identifier to cite or link to this item: http://dora.health.qld.gov.au/qldresearchjspui/handle/1/86
Title: Assessment of the 2016 National Institute for Health and Care Excellence high-sensitivity troponin rule-out strategy
Authors: Pickering, J. W. 
Cullen, L. 
Body, R. 
Carlton, E. W. 
Kendall, J. 
Greenslade, J. 
Greaves, K. 
Than, M. 
Parsonage, W. A. 
Khattab, A. 
Issue Date: 2018
Source: 104, (8), 2018, p. 665-672
Pages: 665-672
Journal: Heart
Abstract: OBJECTIVE: We aimed to evaluate the limit of detection of high-sensitivity troponin (hs-cTn) and Thrombolysis In Myocardial Infarction (TIMI) score combination rule-out strategy suggested within the 2016 National Institute for Health and Care Excellence (NICE) Chest Pain of Recent Onset guidelines and establish the optimal TIMI score threshold for clinical use.METHODS: A pooled analysis of adult patients presenting to the emergency department with chest pain and a non-ischaemic ECG, recruited into six prospective studies, from Australia, New Zealand and the UK. We evaluated the sensitivity of TIMI score thresholds from 0 to 2 alongside hs-cTnT or hs-cTnI for the primary outcome of major adverse cardiac events within 30 days.
RESULTS: Data were available for 3159 patients for hs-cTnT and 4532 for hs-cTnI, of these 376 (11.9%) and 445 (9.8%) had major adverse cardiac events, respectively. Using a TIMI score of 0, the sensitivity for the primary outcome was 99.5% (95% CI 98.1% to 99.9%) alongside hs-cTnT and 98.9% (97.4% to 99.6%)%) alongside hs-cTnI, identifying 17.9% and 21.0% of patients as low risk, respectively. For a TIMI score <=1sensitivity was 98.9% (97.3% to 99.7%)%) alongside hs-cTnT and 98.4% (96.8% to 99.4%)%) alongside hs-cTnI, identifying 28.1% and 35.7% as low risk, respectively. For TIMI<=2, meta-sensitivity was <98% with either assay.
CONCLUSIONS: Our findings support the rule-out strategy suggested by NICE. The TIMI score threshold suggested for clinical use is 0. The proportion of patients identified as low risk (18%-21%) and suitable for early discharge using this threshold may be sufficient to encourage change of practice.
TRIAL REGISTRATION NUMBERS: ADAPT observational study/IMPACT intervention trial ACTRN12611001069943.ADAPT-ADP randomised controlled trial ACTRN12610000766011. EDACS-ADP randomised controlled trial ACTRN12613000745741. TRUST observational study ISRCTN no. 21109279.
Carlton, Edward WattsPickering, John William
Greenslade, Jaimi
Cullen, Louise
Than, Martin
Kendall, Jason
Body, Richard
Parsonage, William A
Khattab, Ahmed
Greaves, Kim
Resources: http://scproxy.slq.qld.gov.au/login?url=http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=28864718http://linksource.ebsco.com/athens.b6e6cc08-c492-42af-aec4-c6084e18e68c/linking.aspx?sid=OVID:medline&id=pmid:28864718&id=doi:10.1136%2Fheartjnl-2017-311983&issn=1355-6037&isbn=&volume=104&issue=8&spage=665&date=2018&title=Heart&atitle=Assessment+of+the+2016+National+Institute+for+Health+and+Care+Excellence+high-sensitivity+troponin+rule-out+strategy.&aulast=Carlton&pid=%3CAN%3E28864718%3C%2FAN%3E
Type: Article
Appears in Collections:Publications

Page view(s)

56
checked on Mar 2, 2020

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.